Structural Analyses of DNA Recognition by the AML1/Runx-1 Runt Domain and Its Allosteric Control by CBFβ

The core binding factor (CBF) heterodimeric transcription factors comprised of AML/CBFA/PEBP2alpha/Runx and CBFbeta/PEBP2beta subunits are essential for differentiation of hematopoietic and bone cells, and their mutation is intimately related to the development of acute leukemias and cleidocranial dysplasia. Here, we present the crystal structures of the AML1/Runx-1/CBFalpha(Runt domain)-CBFbeta(core domain)-C/EBPbeta(bZip)-DNA, AML1/Runx-1/CBFalpha(Runt domain)-C/EBPbeta(bZip)-DNA, and AML1/Runx-1/CBFalpha(Runt domain)-DNA complexes. The hydrogen bonding network formed among CBFalpha(Runt domain) and CBFbeta, and CBFalpha(Runt domain) and DNA revealed the allosteric regulation mechanism of CBFalpha(Runt domain)-DNA binding by CBFbeta. The point mutations of CBFalpha related to the aforementioned diseases were also mapped and their effect on DNA binding is discussed.

[1]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21 , 2000 .

[2]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[3]  M. Cleary.  A new angle on a pervasive oncogene , 1999, Nature Genetics.

[4]  N. Lenny,et al.  Functional domains of the t(8;21) fusion protein, AML-1/ETO. , 1995, Oncogene.

[5]  T. Gu,et al.  Core-binding factor: a central player in hematopoiesis and leukemia. , 1999, Cancer research.

[6]  G. Ghosh,et al.  Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA , 1998, Nature.

[7]  Yoshiaki Ito,et al.  Molecular Cloning and Characterization of PEBP2β, the Heterodimeric Partner of a Novel Drosophila runt-Related DNA Binding Protein PEBP2α , 1993 .

[8]  S. Harrison,et al.  Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA , 1998, Nature.

[9]  J. Yodoi,et al.  Redox Regulation of the DNA Binding Activity in Transcription Factor PEBP2 , 1997, The Journal of Biological Chemistry.

[10]  D. Tenen,et al.  Multiple Functional Domains of AML1: PU.1 and C/EBPα Synergize with Different Regions of AML1 , 1998, Molecular and Cellular Biology.

[11]  M. H. Werner,et al.  Molecular insights into PEBP2/CBFβ-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBFβ , 1999, Nature Structural Biology.

[12]  J. Kelley,et al.  Biophysical characterization of interactions between the core binding factor α and β subunits and DNA , 2000 .

[13]  C. Müller,et al.  Crystallographic structure of the T domain–DNA complex of the Brachyury transcription factor , 1997, Nature.

[14]  S. Harrison,et al.  Structure of the NF-kappa B p50 homodimer bound to DNA. , 1995, Nature.

[15]  V. Dötsch,et al.  Solution Structure of the Core NFATC1/DNA Complex , 1998, Cell.

[16]  H. Dyson,et al.  Identification of the regions involved in DNA binding by the mouse PEBP2α protein , 2000 .

[17]  T. Komori,et al.  Cbfa1 in bone development. , 1998, Current opinion in genetics & development.

[18]  D. Tenen,et al.  CCAAT Enhancer-Binding Protein ( C / EBP ) and AML 1 ( CBF a 2 ) Synergistically Activate the Macrophage Colony-Stimulating Factor Receptor Promoter , 1995 .

[19]  Chaohong Sun,et al.  The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. , 1999, Structure.

[20]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[21]  N. Kakazu,et al.  PEBP2αA/CBFA1 mutations in Japanese cleidocranial dysplasia patients , 2000 .

[22]  M. H. Werner,et al.  Runt domains take the lead in hematopoiesis and osteogenesis , 1999, Nature Medicine.

[23]  J. Bravo,et al.  Energetic and Functional Contribution of Residues in the Core Binding Factor β (CBFβ) Subunit to Heterodimerization with CBFα* , 2000, The Journal of Biological Chemistry.

[24]  Gregory L. Verdine,et al.  Structure of the human NF‐κB p52 homodimer‐DNA complex at 2.1 Å resolution , 1997 .

[25]  M. Ohki,et al.  The Runt domain identifies a new family of heteromeric transcriptional regulators. , 1993, Trends in genetics : TIG.

[26]  P. Tegtmeyer,et al.  Role of cysteine residues in regulation of p53 function , 1995, Molecular and cellular biology.

[27]  Pei-ji Chen,et al.  An exceptionally well-preserved theropod dinosaur from the Yixian Formation of China , 1998, Nature.

[28]  P. Sigler,et al.  Structure of NF-κB p50 homodimer bound to a κB site , 1998, Nature.

[29]  J. Bushweller,et al.  Biochemical and Biophysical Properties of the Core-binding Factor α2 (AML1) DNA-binding Domain* , 1996, The Journal of Biological Chemistry.

[30]  J. N. Mark Glover,et al.  Crystal structure of the heterodimeric bZIP transcription factor c-Fos–c-Jun bound to DNA , 1995, Nature.

[31]  J. Gergen,et al.  Differential interactions between Brother proteins and Runt domain proteins in the Drosophila embryo and eye. , 1999, Development.

[32]  J. Rowley,et al.  The critical role of chromosome translocations in human leukemias. , 1998, Annual review of genetics.

[33]  Roger L. Williams,et al.  Structural basis for the heterodimeric interaction between the acute leukaemia‐associated transcription factors AML1 and CBFβ , 2000, The EMBO journal.

[34]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.

[35]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[36]  Lei Zhou,et al.  CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. , 1999, Human molecular genetics.

[37]  J. Darnell,et al.  Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA , 1998, Cell.

[38]  N. Speck,et al.  Auto-Inhibition and Partner Proteins , Core-Binding Factor b ( CBF b ) and Ets-1 , Modulate DNA Binding by CBF a 2 ( AML 1 ) , 1999 .

[39]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[40]  J. Bushweller,et al.  Solution structure of core binding factor β and map of the CBFα binding site , 1999, Nature Structural Biology.

[41]  N. Speck,et al.  A new transcription factor family associated with human leukemias. , 1995, Critical reviews in eukaryotic gene expression.

[42]  S. Mundlos,et al.  Mutation analysis of core binding factor A1 in patients with cleidocranial dysplasia. , 1999, American journal of human genetics.

[43]  T. Tahirov,et al.  Crystallization and preliminary X-ray analyses of quaternary, ternary and binary protein–DNA complexes with involvement of AML1/Runx-1/CBFα Runt domain, CBFβ and the C/EBPβ bZip region , 2001 .

[44]  Yoshiaki Ito,et al.  Functional Dissection of the α and β Subunits of Transcription Factor PEBP2 and the Redox Susceptibility of Its DNA Binding Activity* , 1996, The Journal of Biological Chemistry.

[45]  S. Hiebert,et al.  Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. , 2000, Gene.

[46]  A. Baldini,et al.  Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia , 1997, Nature Genetics.

[47]  Cynthia Wolberger,et al.  The Structure of GABPα/β: An ETS Domain- Ankyrin Repeat Heterodimer Bound to DNA , 1998 .

[48]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[49]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[50]  Thierry Soussi,et al.  Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..

[51]  M. Kurokawa,et al.  Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. , 2000, Blood.

[52]  K. Shigesada,et al.  A simple screening for mutant DNA binding proteins: application to murine transcription factor PEBP2alpha subunit, a founding member of the Runt domain protein family. , 1997, Gene.

[53]  G. Nucifora,et al.  AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[54]  B. Chait,et al.  Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain , 2000, Nature Structural Biology.

[55]  V. Dötsch,et al.  Solution Structure of the Core NFATC 1 / DNA , 1998 .

[56]  W. Wooster,et al.  Crystal structure of , 2005 .

[57]  Gregory L. Verdine,et al.  Structure of the NF-κB p50 homodimer bound to DNA , 1995, Nature.

[58]  N. Speck,et al.  Sequence specificity of the core-binding factor , 1993, Journal of virology.

[59]  T. Gu,et al.  Auto-Inhibition and Partner Proteins, Core-Binding Factor β (CBFβ) and Ets-1, Modulate DNA Binding by CBFα2 (AML1) , 2000, Molecular and Cellular Biology.

[60]  Yoshiaki Ito.  Molecular basis of tissue‐specific gene expression mediated by the Runt domain transcription factor PEBP2/CBF , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[61]  Y. Ito,et al.  Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer , 1990, Journal of virology.